2-methyl-N-[(1S)-1-(4-methylcyclohexyl)-2-[4-(oxan-4-yl)anilino]-2-oxoethyl]pyrazole-3-carboxamide
C25H34N4O3 — CID 166871515
Data last refreshed: (MolForge compound catalog, from PubChem)
About 2-methyl-N-[(1S)-1-(4-methylcyclohexyl)-2-[4-(oxan-4-yl)anilino]-2-oxoethyl]pyrazole-3-carboxamide
2-methyl-N-[(1S)-1-(4-methylcyclohexyl)-2-[4-(oxan-4-yl)anilino]-2-oxoethyl]pyrazole-3-carboxamide (PubChem CID 166871515) has the molecular formula C25H34N4O3 and a molecular weight of 438.57 g/mol. Its IUPAC name is 2-methyl-N-[(1S)-1-(4-methylcyclohexyl)-2-[4-(oxan-4-yl)anilino]-2-oxoethyl]pyrazole-3-carboxamide.
Molecular Properties
| Compound Name | 2-methyl-N-[(1S)-1-(4-methylcyclohexyl)-2-[4-(oxan-4-yl)anilino]-2-oxoethyl]pyrazole-3-carboxamide |
|---|---|
| PubChem CID | 166871515 |
| Molecular Formula | C25H34N4O3 |
| Molecular Weight | 438.57 g/mol |
| Exact Mass | 438.26 |
| IUPAC Name | 2-methyl-N-[(1S)-1-(4-methylcyclohexyl)-2-[4-(oxan-4-yl)anilino]-2-oxoethyl]pyrazole-3-carboxamide |
| SMILES | CC1CCC([C@H](NC(=O)c2ccnn2C)C(=O)Nc2ccc(C3CCOCC3)cc2)CC1 |
| InChI | InChI=1S/C25H34N4O3/c1-17-3-5-20(6-4-17)23(28-24(30)22-11-14-26-29(22)2)25(31)27-21-9-7-18(8-10-21)19-12-15-32-16-13-19/h7-11,14,17,19-20,23H,3-6,12-13,15-16H2,1-2H3,(H,27,31)(H,28,30)/t17?,20?,23-/m0/s1 |
| InChIKey | MKJDXCQRSJSATR-MLFGXNJISA-N |
| XLogP | 3.88 |
| TPSA | 85.25 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 5 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 32 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 438.57 |
| LogP ≤ 5 | 3.88 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 5 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 166871515 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.